Skip to the beginning of the images gallery

SERMORELIN 5MG

SKU

PN-SRM-5

Rating:

97 % of 100

15 Reviews Add Your Review

In stock

$49.99

Buy 5 for $44.99 each and save 10%
Buy 10 for $39.99 each and save 20%

499.9 Reward Points will be used to purchase this product

Buy this product and Earn 20.00 Pinnacle Points click here to login

Ship to

Calculate Shipping Cost

Country

State/Province

Zip/Postal Code

Qty

Add to Wish List

BACTERIOSTATIC WATER

For this product you will need: BACTERIOSTATIC WATER For reconstitution.

Overview

The chemicals/materials for sale here are intended for laboratory and research use only, unless otherwise explicitly stated. They are not intended for human ingestion or for use in products that may be ingested.

What Is SERMORELIN 5MG?

Sermorelin is a man-made analog of growth hormone-releasing hormone (GHRH). It is the shortest synthetic peptide comprised of 29 amino acids that can produce biological activity. In the past, it served as a means for treating and diagnosing growth hormone deficiency in children. Currently, it is being researched for its role in sleep quality, cardiac remodeling, brain tumor and lipodystrophy. At Pinnacle Peptide, sermorelin for sale is exclusively available for research and experimentation.

Structure Of SERMORELIN 5MG

From Pubchem

Synonyms: Sermorelina, 86168-78-7, Somatoliberin
Molecular Formula: C149H246N44O42S
Molecular Weight: 3357.9 g/mol Sequence: YADAIFTNSYRKVLGQLSARKLLQDIMSR
CAS number: 86168-78-7
PubChem CID: 16132413

History

Sermorelin was first developed in the 1980s in the United States. Following the successful completion of clinical trials, it was approved in 1997 for the diagnosis and treatment of growth hormone deficiency in children. It was sold under the brand name, Geref. Later on, the FDA withdrew its approval in 2008 because of commercial reasons unrelated to its safety and efficacy. Since then, it has been discontinued by the manufacturer and is not available in the US.

Mechanism Of SERMORELIN 5MG

As a GHRH analog, it binds to growth hormone-releasing hormone receptors in the anterior pituitary gland. This, in turn, signals the body to produce and release more GH through somatotropic cells. Unlike the recombinant growth hormone, it doesn’t raise GH in the body to supraphysiological levels. In fact, it mimics the function of endogenous growth-releasing factor and increases the physiological secretion of GH to the maximum level.

Pre-Clinical/Clinical Research

1. Cardioprotection

Sermorelin exhibits cardioprotective effects. It has been shown to decrease cardiac remodeling and scarring following myocardial infarction. One study conducted on swine with ischemic cardiomyopathy found that GHRH analog reduced the size of infarct and improved diastolic strain. Furthermore, the activation of GHRH receptors initiated the signaling for the repairing process [1].

Similarly, another study reports that GHRH agonists can suppress inflammatory responses after a heart attack. Plus, these agents have the tendency to increase the number of blood vessels in the damaged area and reduce the death of cardiomyocytes. In short, sermorelin can improve the process of healing and cardiac remodeling through pathways involved in fibrosis, apoptosis and cardiac repair [2].

2. Lipodystrophy

In the case of AIDS, the use of highly active antiretroviral therapy (HAART) has been shown to be associated with the development of lipodystrophy. It is an abnormal condition characterized by the uneven distribution of body fat. It may cause patient distress and lead to poor adherence to the therapy. Furthermore, low levels of growth hormones are observed in men with HIV lipodystrophy [3].

One study was conducted to test the hypothesis that GHRH analog can be used to treat/manage lipodystrophy in AIDS patients. 31 HIV men were recruited and randomized to receive either placebo or GHRH analog twice daily for 12 weeks. The results found that the treatment effectively increased the concentration of insulin-like growth factor-1. Plus, it also improved total and regional body composition, improved lean mass and reduced visceral fat. These findings indicate that GHRH agonists, including sermorelin, might potentially be a beneficial treatment strategy for HIV patients with lipodystrophy [4].

3. Antiaging Effects

The age-related changes are associated with a decrease in the levels of GH as people get older. GHRH analogs stimulate IGF-1 concentration and increase pituitary preserve. It also might be able to restore the neuroendocrine axis and promote youthful physiology in aging individuals [5].

One study involving elderly male and female participants was conducted to check the effect of GHRH analog on aging. Participants self-injected themselves with placebo for 4 weeks followed by a 16-week administration of a GHRH analog. The administration of the GHRH analog at night resulted in a rapid increase in growth hormone levels within 10 minutes, which was sustained for up to 2 hours. Additionally, the results revealed elevated levels of IGF-1 and IGFBP3, increased skin thickness, and an increase in lean body mass. Notably, improvements in insulin sensitivity and libido were observed in men, suggesting a more pronounced treatment effect on women [6].

4. Sleep Quality

Research shows that orexin, a neurochemical produced by the brain, plays an important role in the regulation of the sleep cycle. Studies show that sermorelin and other GHRH agonists can boost orexin levels, thus improving sleep quality [7]. Furthermore, poor sleep is associated with age-related cognitive decline. The beneficial effects of GHRH analog, including sermorelin, on sleep might be because of its ability to enhance cognitive skills [8].

5. Growth Hormone Deficiency Disorder

Sermorelin produces the same effect as recombinant growth hormone. It builds muscle mass, boosts strength and enhances performance. However, sermorelin is preferred over recombinant growth hormone as it causes fewer side effects. It mimics the physiological process and is subjected to feedback mechanisms, thus preventing adverse effects like improper dosing and disruption of normal processes.

Furthermore, it is not affected by tachyphylaxis. It is a condition in which the body’s response to a drug is lost after repeated exposure and requires higher doses to achieve the desired effects [5].

Summary

Sermorelin is a GHRH analog that binds with growth hormone releasing-hormone receptors in the anterior pituitary gland. It stimulates the release of growth hormone and has been shown to reduce scaring and cardiac remodeling following myocardial infarction. Further, it has the potential to treat HIV-associated lipodystrophy, improve sleep quality and reverse age-related changes. It is no longer FDA-approved and is not available in the US market for therapeutic purposes. We don’t support its unwarranted use and offer sermorelin purchase exclusively for research. Only buy sermorelin if you are an authorized researcher.